Lexicon Pharmaceuticals, Inc. has released its fourth quarter and full-year 2025 financial results alongside a comprehensive earnings call presentation highlighting significant pipeline advancements and improved financial performance.5051
Financial Highlights
The company reported total revenues of $5.5 million for Q4 2025, including $4.3 million from the Novo Nordisk licensing agreement and $1.1 million in net sales of INPEFA. This marks a notable performance amid ongoing pipeline investments. Net loss narrowed to $15.5 million, or $0.04 per share, compared to $33.8 million, or $0.09 per share, in Q4 2024.50
For the full year 2025, revenues reached $49.8 million, driven by $45.0 million in licensing revenue and $4.6 million from INPEFA net sales. Annual net loss improved sharply to $50.3 million, or $0.14 per share, from $200.4 million, or $0.63 per share, in 2024. Research and development expenses declined to $61.1 million from $84.5 million, while selling, general, and administrative costs dropped to $37.3 million from $143.1 million.50
Cash, cash equivalents, short-term investments, and restricted cash stood at $125.2 million as of December 31, 2025. In February 2026, Lexicon received approximately $96.7 million in net proceeds from a stock sale and a $10 million milestone payment from Novo Nordisk, bolstering its position with over $100 million in additional cash.50
Pipeline Progress
Sotagliflozin in Cardiometabolic Disorders
Enrollment in the pivotal Phase 3 SONATA-HCM study for hypertrophic cardiomyopathy (HCM) advances, with over 50% complete across 130 sites in 20 countries. Topline results are expected in Q1 2027, targeting improvements in symptoms and quality of life via the KCCQ Clinical Summary Scale.51
For type 1 diabetes (T1D), the company plans NDA resubmission for ZYNQUISTA in 2026, supported by data from the STENO-1 investigator-initiated study, following positive FDA feedback.5051
Pilavapadin and LX9851
The FDA End-of-Phase 2 meeting for pilavapadin (LX9211) in diabetic peripheral neuropathic pain (DPNP) confirmed readiness for Phase 3, with two planned 12-week placebo-controlled studies. Partnership discussions continue.5051
LX9851, licensed to Novo Nordisk for obesity and cardiometabolic disorders, completed IND-enabling studies. An additional $20 million in milestones remains possible in 2026.50
Executive Commentary
“The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” stated Mike Exton, Ph.D., CEO and Director. “We made substantial progress on all aspects of the business by advancing our pipeline programs, establishing strong development and commercialization agreements with leading global collaborators, working closely with regulators, and remaining operationally efficient.”50
Scott Coiante, SVP and CFO, added, “Our recent capital raise and milestone payment received from Novo Nordisk resulted in more than $100 million in additional cash in February 2026, which together with our rigorous expense discipline in 2025, provides the financial footing needed to support our pipeline programs.”50
Lexicon positions 2026 for key catalysts, including SONATA-HCM topline data, potential T1D approval, and expanded partnerships.51
